Background: The aim of the study was to investigate if there were differences in associations of stromal versus intratumoral tumor infiltrating lymphocytes (TILs) with pathology complete response (pCR) among breast cancer (BC) subtypes treated with neoadjuvant therapy.
Background: The aim of the study was to investigate if there were differences in associations of stromal versus intratumoral tumor infiltrating lymphocytes (TILs) with pathology complete response (pCR) among breast cancer (BC) subtypes treated with neoadjuvant therapy.
Materials and Methods:
The hematoxylin and eosin slides of BCcore biopsy consecutive cases (n = 331) were reviewed from a single institution between 2000 and 2014. TIL-stroma (TIL-str) was scored from 0% to 100%. Intratumoral lymphocytes (iTuLy) were scored semiquantitatively incorporating the infiltrate grade (0 to 3) and the corresponding percentage resulting in a score ranging from 0 to 300. pCR was defined as no residual infiltrating tumor in the tumor bed and the lymph nodes.
Results: pCR was achieved in 29 of 95 (30.9%) triple negative cases, 25 of 77 (32.5%) HER2+, and 9 of 159 (5.6%) luminal tumors. In univariate analysis, invasive nonlobular carcinoma, higher Nottingham grade, nonluminal subtypes, trastuzumab therapy, nonadvanced clinical T stage (T1 and T2), TIL-str, and iTu-Ly-predicted pCR. In luminal subtype, iTu-Ly but not TILstr was an independent predictor for pCR [odds ratio (OR) = 1.44, 95% confidence interval (CI), 1.08-1.9, P = 0.013]. In triple negative subtype, both TIL-str and iTu-Ly were independent predictors for pCR (OR = 1.68, 95% CI, 1.29-2.18, P = 0.001; OR = 1.31, 95% CI, 1.05-1.63, P = 0.017, respectively). In HER2+ subtype, neither TIL-str nor iTu-Ly predicted pCR.
Conclusions: TILs are variably correlated with better neoadjuvant chemotherapy response depending on their location and clinical subtype of BC. It could indicate that TILs might be functionally heterogeneous with regard to their role in mediating antitumor immune response, depending on their location and BC subtypes.
Key Words: tumor infiltrating lymphocytes, breast cancer, neoadjuvant therapy, pathology complete response (Appl Immunohistochem Mol Morphol 2018;26:523-532) P roliferation and invasion of malignant tumor cells is controlled by a complex system. One of the factors is the interaction between the tumor cells and the host immune cells. It is known that tumor-immune system interaction is critical in development and progression of many solid tumors. There is a wide interest in immunotherapies in breast cancer (BC). Number of clinical studies has shown that the presence of a lymphocytic infiltrate in various types of cancer tissues including breast is associated with improved outcome, [1] [2] [3] [4] [5] [6] [7] [8] but are limited by methodology and not considering different clinical subtypes of BC in any given study.
There are studies that evaluated tumor infiltrating lymphocytes (TILs) in BC in both the stromal and intratumoral compartments separately. 6 Intratumoral TILs (iTu-Ly) are defined as lymphocytes in direct cell-to-cell contact with the tumor cells with no intervening stroma. Stromal TILs (TIL-str) are located scattered or clustered in the stroma between the carcinoma cells/clusters and do not directly interact with tumor cells. 9 Although the original hypothesis was that lymphocytes directly interacting with carcinoma cells are more biologically relevant, 9 most current studies have found that TIL-str to be superior to iTu-Ly and a more reproducible parameter in predicting response to therapy. 9 That is mainly due to the difficulty recognizing and scoring iTu-Ly when embedded in the tumor compared with TIL-str. When interpreting TILs in histologic tissue sections, they are assumed to be in a static situation which may be artificial, because lymphocytes move in the microenvironment in a living tissue.
TILs have been studied in various clinical trials and institutional cohorts of BC. It was found that there was heterogeneity in the association of TILs with pathologic complete response (pCR): it was more consistent in triple negative (TN) than in human epidermal growth factor receptor 2 (HER2)+ BC, and the least consistent in luminal/HER2 À cases. [10] [11] [12] [13] [14] We hypothesized that tumor-immune interactions add another layer of tumor heterogeneity across tumor subtypes. Our hypothesis was built on 2 observations. First, it is possible that there are biological differences between the lymphocytes close to the tumor cells and those separate from the tumor and embedded in the stroma. Second, there are differences in the relationships between TILs and different subtypes in terms of the response to cytotoxic neoadjuvant therapy (NAT) regimens. To test this hypothesis, we investigated if there were differences in associations of TILs with pCR among BC subtypes and if TILs location differentially predicted pCR in patients treated with NAT. To overcome the issue of accurately scoring iTu-Ly, we developed a semiquantitative scoring system incorporating the degree of infiltration and the percentage of involved tumor cells.
MATERIALS AND METHODS

Collection of Pretherapeutic Core Biopsies and Exclusion Criteria
Paraffin-embedded pretherapeutic core biopsies from our institution (n = 100) and from the referring institutions (n = 231) for a total of 331 cases were used in this study. We excluded skin biopsies with ulceration due to the difficulty in interpreting TILs. Also, cases with microinvasive carcinoma, missing biomarkers results, or tumor only represented in a lymph node biopsy with no biopsy of the primary tumor available were excluded.
Patients
Consecutive BC biopsies (n = 331) from our institution between 2000 and 2014 were reviewed. Standard clinicopathologic characteristics were abstracted from the BC database including patient age, race, tumor histologic type, Nottingham grade, clinical T stage (1 to 4), clinical N stage (0 to 3), chemotherapy regimen, trastuzumab use, and pathology stage. pCR is defined as no residual invasive carcinoma in the tumor bed or lymph node involvement (y-T0/is and N0). All these patients had locally advanced disease and treated with neoadjuvant cytotoxic chemotherapy.
Estrogen and progesterone receptors were scored using Allred scoring system as previously described. 15 HER2 status was abstracted from the pathology reports. Using these 3 markers, 3 clinical subtypes were classified: luminal/HER2À was defined as BC with estrogen receptor (ER)+ and/or progesterone receptor (PR)+ and HER2À ; TN was ERÀ /PRÀ /HER2À ; and HER2+ was HER2+ regardless of ER or PR status. 16 We acknowledge the limitation of using only these 3 markers in subclassifying BC. However, we adopted this classification based only on the different therapies that these patients receive where patients with HER2+ receive anti-HER2 therapies, and patients with triple negative breast cancer (TNBC) receive more aggressive therapies than luminal/ HER2À .
TILs Scoring
Histopathologic scoring of TILs was jointly performed on hematoxylin and eosin-stained sections by 2 pathologists (T.K. and V.N.). Two types of scoring systems were applied to evaluate TIL-str and iTu-Ly. Although the first was located in the stroma separate from the tumor, the latter was intimately located next to the tumor cells. TIL-str was scored following the International TILs Working Group 2014 recommendation (Fig. 1) . 9 iTu-Ly was scored using a semiquantitative scoring system (H score) that included the grade of lymphocytic infiltration (0 to 3) (Fig. 2 ) and the percentage of tumor harboring each grade. The grade of iTu-Ly ranged from 0 to 3, where 0 = virtually no lymphocytes, 1 = sparse intratumoral lymphocytes seen only under x40 magnification, 2 = frequent easily recognized lymphocytes seen under x20 magnification, and 3 = tumor is obscured by lymphocytes. The final score was the sum total of the products of multiplying the grade and the corresponding percentage, resulting a score ranging from 0 to 300. For example, for a tumor with 40% grade 0, 20% grade 1, 20% grade 2, and 20% grade 3, the final score would be 40 Â 0+20 Â 1+20 Â 2+20 Â 3 = 150.
Training Set
To validate our scoring systems (iTu-Ly and TILstr), a group of 100 breast carcinoma core biopsies was independently scored by 2 pathologists (T.K. and V.N.). For TIL-str, the percentage of lymphocytes was recorded. For iTu-Ly, the percentage of each grade (0, 1, 2, and 3) was recorded. Then, the scores were compared by calculating the percentage agreement and the weighted k values.
Statistical Analysis
The clinicopathologic characteristics for a total of 331 patients included age, race, tumor histology type, Nottingham grade, clinical T stage, clinical N stage, trastuzumab use, ER, PR status and corresponding Allred scores, HER2 status, BC subtypes, TIL-str, and iTu-Ly. Univariate analysis was first performed to evaluate the association between pCR and clinicopathologic variables. The Fisher exact test was used for categorical variables and Wilcoxon nonparametric test for continuous variables. The significant clinicopathologic variables in the univariate analysis were then included in the multivariate analysis by logistic regression. All variables that found to be significant in the univariate analysis for each group were included in the multivariate analysis. The odds ratios (ORs) with their 95% confidence intervals (CIs) and 2-sided P-values were reported for each variable. Similar approaches were performed in each subgroup of patients (TN, luminal and HER2+). All reported tests were conducted at a nominal significance level of 0.05.
Statistical analysis was performed using R version 3.2.2 (http://www.r-project.org).
The degree of agreement between the observers is calculated by k statistics. The paired agreement is calculated by squared weighted k. The guidelines characterize weighted k values as follows: 0 to 0.2 as poor, 0.21 to 0.4 as fair, 0.41 to 0.6 as moderate, 0.61 to 0.8 as substantial, and 0.81 to 1 as almost perfect agreement.
RESULTS
Interobserver Agreement in the Training Group
In this group (n = 100), there were 88 cases of no special type and 12 of lobular type. There were 41 ER+/ HER2 À , 39 TN, and 20 HER2+. The agreement between the observers was 46% for TIL-str with k value of 0.64 (substantial agreement, P < 0.0001) and 36% with k value of 0.51 (moderate agreement, P < 0.0001). The k values for iTu-Ly grades 0, 1, 2, and 3 were 0.55, 0.76, 0.77, and 0.87 (P < 0.0001 for each). Then the cases were divided into 3 groups using cutoffs recommended by IssaNummer et al, 17 as follows, TIL-str (0, >0 to <60, Z60); iTu-Ly (0, >0 to <180, Z180). The agreement for TIL-str was 91% with k value of 0.69 (substantial, P < 0.0001) and for iTu-Ly 82% with k value of 0.72 (substantial, P < 0.0001). However, we acknowledge fact that these cutoffs are not widely used.
Correlation Between TILs and pCR in All Cases
There were a total of 63 (19%) patients who had pCR in all BC subtypes. The overall median and range of TILstr and iTu-Ly score were 20 (0 to 90) and 80 (0 to 300), respectively. Spearman correlation coefficient between TILstr and iTu-Ly scores was 0.707 (P < 0.001) (Fig. 3A) . Both TIL-str and iTu-Ly scores were highly significant in predicting pCR. Patients with pCR has a higher TIL-str score than those with non-pCR [median range, 30 (0 to 90) vs. 10 (0 to 90), P < 0.001]. Similarly, patients with pCR had higher iTu-Ly score than those with non-pCR [130 (0 to 300) vs. 50 (0 to 300), P < 0.001]. In addition, invasive nonlobular carcinoma, higher Nottingham grade, nonluminal subtypes, ERÀ , PRÀ , HER2+, nonadvanced clinical T stage (T1 and T2), and trastuzumab therapy were associated with pCR (Table 1) .
In multivariate analysis using TIL-str as TILs variable, nonadvanced clinical T stage (T1 and T2), TIL-str, and nonluminal subtypes were independent predictors of pCR. TIL-str score was a significant independent variable (P < 0.001), with OR of 1.39 (95% CI, 1.18-1.62) per 10% increase in the lymphocyte infiltrate (Table 2 ). In multivariate analysis using iTu-Ly as TILs variable, nonadvanced clinical T stage (T1 and T2), trastuzumab therapy, iTu-Ly and nonluminal subtypes were independent predictors of pCR. iTu-Ly score was a significant independent variable (P < 0.001), with OR of 1.28 (95% CI, 1.11-1.46) per a score of 30 increase in the lymphocyte infiltrate (Table 2) .
Correlation Between TILs and pCR in Luminal Subtype
There were 159 (48%) luminal A cases, 9 (5.7%) of which had pCR. Both iTu-Ly and TIL-str were statistically significant in predicting pCR. The median and range of TIL-str in the cases with pCR versus non-pCR was 20 (10 to 50) versus 10 (0 to 90), respectively (P = 0.021). The median and range of iTu-Ly in the cases with pCR versus non-pCR was 120 (10 to 220) versus 50 (0 to 270), respectively (P = 0.008) (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/AIMM/ A143). However, iTu-Ly (P = 0.013) but not TIL-str (P = 0.174) predicted pCR in multivariate analysis with OR of 1.44 (95% CI, 1.08-1.91) per a score of 30 increase in the lymphocyte infiltrate (Table 3) . It is worth noting that ER À /PR+ phenotype (n = 10) was independent predictor for pCR with borderline significance (P = 0.061 using TIL-str variable and P = 0.056 using iTu-Ly variable; Table 3 ). Spearman correlation coefficient between TIL-str and iTu-Ly scores was 0.711 (P < 0.0001).However, there was clustering for cases with pCR in the region of high iTu-Ly and low TIL-str (Fig. 3B) . Figure 4 shows an example of high iTu-Ly infiltrate in luminal type BC. 
Correlation Between TILs and pCR in TN Subtype
There were 95 (26.8%) TN cases, 29 (30.5%) of which had pCR. Patient's age, TIL-str, and iTu-Ly were statistically significant in predicting pCR. The median and range of TIL-str in the cases with pCR versus nonpCR was 20 (0 to 80) versus 50 (0 to 90), respectively (P < 0.001). The median and range of iTu-Ly in the cases with pCR versus non-pCR was 100 (0 to 200) versus 150 (20 to 300), respectively (P = 0.014) (Supplemental Table 2, Supplemental Digital Content 2, http://links. lww.com/AIMM/A144).
In multivariate analysis, TIL-str score was a significant independent variable (P = 0.001), with OR of 1.68 (95% CI, 1.29-2.18) per a score of 10 increase in the lymphocyte infiltrate (Table 4) . iTu-Ly score was also a significant independent variable (P = 0.017), with OR of 1.31 (95% CI, 1.05-1.63) per a score of 30 increase in the lymphocyte infiltrate (Table 4) . Spearman correlation coefficient between TIL-str and iTu-Ly scores was 0.654 with more even distribution of cases with pCR in terms of TIL-str and iTu-Ly scores (P < 0.0001; Fig. 3C ).
patients for 1 of 3 reasons: (1) patients (n = 6) had their disease before mid-2005 when trastuzumab was first implemented in the neoadjuvant setting; (2) patient (n = 1) was on a clinical trial; or (3) patients (n = 2) deemed not tolerant to this agent. None of the patients who did not receive trastuzumab (n = 9) achieved pCR. Therefore, the rate of pCR to trastuzumab was 25 of 68 (36.8%). Only nonadvanced clinical T stage (T1 and T2) predicted pCR (P = 0.036). All other variables, including TIL-str and iTu-Ly were not statistically significant ( Table 5 ). The overall median and range of TIL-str and iTu-Ly was 20 (0 to 70) and 60 (0 to 250), respectively. The median and range of TIL-str in the cases with pCR versus non-pCR was 20 (0 to 70) versus 20 (0 to 70), respectively (P = 0.74). The median and range of iTu-Ly in the cases with pCR versus non-pCR was 90 (0 to 250) versus 55 (0 to 190), respectively (P = 0.38) (Supplemental Table 3 , Supplemental Digital Content 3, http://links.lww.com/ AIMM/A145). Multivariate analysis was not performed due to the lack of >1 significant variable in univariate analysis. Spearman correlation coefficient between TILstr and iTu-Ly scores was 0.644 (P < 0.0001; Fig. 3D ).
Then HER2+ cases were further divided into 2 subgroups: ER+ and/or PR+ and ER À /PR À . In ER+ and/or PR+ group, lower ER or PR scores predicted pCR in univariate analysis (P = 0.003 and 0.11, respectively), as well as nonadvanced clinical T stage (T1 and T2; P = 0.003) (Supplemental Table 4 , Supplemental Digital Content 4, http://links.lww.com/AIMM/A146). None of these variables was statistically significant in multivariate analysis. In ER À /PR À subgroup, none of the variables was statistically significant (Supplemental Table 5 , Supplemental Digital Content 5, http://links. lww.com/AIMM/A147). When cases without trastuzumab therapy were excluded, none of the variables, including both TILs patterns, was statistically significant.
DISCUSSION
To our knowledge, this is the first study that investigated the role of TILs location in response to NAT in various BC clinical subtypes. We found that both TIL-str and iTu-Ly were independent predictors of pCR when all BC cases were considered together. However, when taking the clinical subtype of BC into considerations the results differed. In luminal subtype lymphocytes that were intimate to tumor cells but not stromal lymphocytes predicted pCR. Regardless of TILs location, they predicted pCR in TN subtype but not in HER2+ subtype independent of hormonal receptor status.
Although some investigators have suggested that the location of TILs was biologically insignificant since these cells were scored as they were artificially static, 9 some others suggested otherwise. It is known that stroma but not tumor harbors various components that influence the host immune response, including fibroblasts, macrophage lineage cells and vascular endothelial cells, with variable amounts of extracellular matrix. These components, in addition to positively regulate tumor growth, can impair host immune responses. 18 This theory is supported by the observation that pure tumor cells were rejected more easily by mice when implanted in vivo than tumors containing stromal elements. 19 For example, Doug and colleagues generated mice that allowed deletion of fibroblast activating protein expressing cells in vivo, which could eliminate these fibroblasts from the tumor microenvironment. This led to tumor regression by a mechanism that was dependent on host immunity. 20 These observations may explain our findings that the lymphocytes in the tumor predictive of response to cytotoxic chemotherapeutic agents. However, it is unclear why only luminal BC had this property of iTu-Ly-significant/TIL-str-nonsignificant. We assume that this subtype may have unique biologic factors that interact with tumoral but not stromal lymphocytes; an area could be targeted for future studies. Also, it should be noted that the number of cases that had pCR in the luminal was relatively small (n = 9). Therefore, more studies like ours are needed to ascertain our findings. We found strong correlation coefficient between TIL-str and iTu-Ly in our study. That is consistent with the findings by Denkert et al 6 who found a correlation coefficient of 0.61 in the training cohort and 0.80 in the validation cohort. In the training group, we found that the agreement between the 2 observers substantial for TIL-str and moderate for iTu-Ly. The main issue with scoring iTu-Ly was recognizing grade 0 (virtually no lymphocytes). All other grades had substantial to almost perfect agreements between the 2 observers. That is because some cell may be difficult to recognize (lymphocyte vs. apoptotic body). When the cases were divided into 3 groups based on cutoffs recommended by Issa-Nummer et al 17 the agreement became substantial for both scoring systems. Although we think iTu-Ly scoring system is valid, we recommend more independent studies to test its reproducibility.
In a meta-analysis including 12 studies, there was significant correlation between TILs and NAT response in all BC subtypes including ER À , TN, HER2+, and HER2 À , but not ER+ with OR 6.21 (95% CI, 0.86-45.15, P = 0.071). 10 However, these studies included all ER+ cases with or without HER2+. In a study conducted by Wang-Lopez and colleagues, 10% of 68 patients with luminal subtype had pCR. They found that TIL-str >15% predicted response to NAT. However, no more details are available regarding the study design and if TIL-str is an independent factor in predicting pCR. 14 Issa-Nummer and colleagues studied a subgroup of GeparQuinto clinical trial including HER2 À cases only [hormonal receptor positive (equivalent to our luminal type) and TN]. In hormonal receptor positive subtype, 12% of 209 cases had pCR. The pCR rate for lymphocytic predominant BC (defined Z60%) was 28.2% (11 pCRs of 39 tumors), whereas it was only 8.2% (14 pCRs of 170 tumors) for nonlymphocytic predominant tumors. However, the investigators did not perform multivariate analysis to evaluate if TILs are independent factor in this tumor subtype. Also, they did not examine if the location of TILs (stromal or intratumoral) differentially predict pCR. 17 Both TIL-str and iTu-Ly were statistically significant as independent factors in predicting pCR in TNBC. Multiple studies have shown that TILs could predict pCR in TNBC patients treated with NAT. In the above meta-analysis of 12 studies, TILs was found to predict pCR with OR, 2.49 (95% CI, 1.61-3.83, P = 0.000). 10 Denkert and colleagues investigated TILs' role in achieving pCR in a subset of TN subtype in GeparSixto trial where TNBC patients received cytotoxic chemotherapy plus bevacizumab. They found significant correlation between lymphocytic predominant BC and pCR in both univariate and multivariate analyses. However, in a subgroup treated with nonpegylated liposomal doxorubicin and carboplatin, TILs did not predict pCR. Although the investigators scored both TIL-str and iTu-Ly, they did not evaluate them separately in terms of predicting pCR. 13 The response rate to trastuzumab-based NAT of 36.8% is consistent with the findings of 2 previous clinical trials (31.7% in GeparQuattro study 21 and 29% in NeoSphere study 22 ). We did not find significant correlation between any of the 2 types of TILs (TIL-str or iTu-Ly) and the response to trastuzumab-based NAT. Several other studies investigated the predictive role of TILs in HER2 BC with varied results. Similar to the findings in our study, a retrospective analysis of samples from NeoSphere clinical trial did not show any correlation between detection of TILs and pCR. However, they found that the expression of immune genes/metagenes had different associations with pCR. 12 In contrast, other studies have shown correlation between TILs and pCR in this tumor type. In the NeoALTTO trial, they found that TILs > 5% were associated with higher pCR rates independent of treatment regimens. 11 In a subgroup analysis of GeparSixto trial, Denkert and colleagues investigated the role of TILs in HER2+ patients who received trastuzumab and lapatinib. They found that TIL-str, as well as lymphocytic predominant BC, was significant in predicting pCR in univariate and multivariate analyses. However, when the definition of pCR changed from ypT0 ypN0 to ypT0is ypN0, the interaction between therapy and lymphocytic predominant BC was not significant. 13 Interestingly, analysis of patients in N9831 revealed that addition of trastuzumab to therapy of HER2+ patients with TIL-str lead to worse progression-free survival. 23 Overall these data might suggest that HER2+ disease and its interaction with host immune system might not be clearly reflected just by analyzing TILs and more functional assays might be required to truly determine prognostic and predictive role of infiltrating lymphocytes.
In this study, we show that the degree of TILs inform on chances of achieving pCR with use of chemotherapy uniquely to each clinical subtype of BC. In luminal subtype only iTu-Ly were shown to correlate to achieving pCR. In TNBC presence of lymphocytic infiltrate independent of its location strongly correlated with pCR. In HER2+ disease, independent of hormonal receptors status, neither TIL-str nor iTu-Ly correlated with pCR reflecting conflicting results from previous investigations. Therefore, one has to be cautious of using presence of TILs as a prognostic marker without taking into account other tumor characteristics.
We have 2 limitations to our study; first, the number of luminal cases that achieved pCR was too small to make strong conclusions; and second, it was retrospective study where the patients treated with different chemotherapy regimens. Our results suggest that TILs might be functionally heterogeneous with regard to their role in mediating antitumor immune response, depending on their location and BC subtypes. More studies using a similar approach are needed to further examine our hypothesis and validate our findings.
